Drug Price Trends for MIRABEGRON ER

Average Pharmacy Cost for MIRABEGRON ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
MIRABEGRON ER 25 MG TABLET	68180-0151-09	10.07501	EACH	2025-05-21
MIRABEGRON ER 25 MG TABLET	70710-1159-03	10.07501	EACH	2025-05-21
MIRABEGRON ER 50 MG TABLET	68180-0152-09	9.49095	EACH	2025-05-21
MIRABEGRON ER 25 MG TABLET	68180-0151-06	10.07501	EACH	2025-05-21
MIRABEGRON ER 25 MG TABLET	70710-1159-09	10.07501	EACH	2025-05-21
MIRABEGRON ER 50 MG TABLET	70710-1160-09	9.49095	EACH	2025-05-21

Market Analysis and Price Projections for Mirabegron ER

Overview of Mirabegron ER

Mirabegron, marketed under the brand name Myrbetriq, is a beta-3 adrenergic receptor agonist used primarily for the treatment of overactive bladder (OAB). It works by relaxing the bladder muscle, allowing it to store more urine and reducing the frequency of urination[4].

Market Size and Growth

The global market for overactive bladder treatments, including mirabegron, is projected to experience steady growth. Here are some key market metrics:

• The global OAB drug market is expected to grow from $2.2 billion in 2020 to $2.8 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 2.7%[1].
• Another forecast indicates that the OAB treatment market will reach $5.33 billion by 2028, growing at a CAGR of 3.1% from 2022 to 2028[3].

Market Drivers

Several factors are driving the growth of the mirabegron market:

• Increasing Prevalence of OAB: The prevalence of OAB is expected to rise due to aging populations, which will expand the treatment pool[1][4].
• Growing Geriatric Populations: Older adults are more likely to suffer from OAB, making this demographic a significant driver for the market[4].
• Heightened Healthcare Awareness: Improved awareness and diagnosis rates among healthcare professionals will contribute to market growth[1][4].

Market Restraints

Despite the growth potential, there are several challenges facing the mirabegron market:

• High Drug Costs: The cost of mirabegron is relatively high, with a 30-tablet supply costing around $432 to $494, depending on the pharmacy and whether it is the brand name or generic version[2][5].
• Limited Insurance Coverage: Issues with insurance coverage and reimbursement can limit accessibility to mirabegron[4].
• Patent Expiry and Generic Competition: The market value is expected to decline in the early-to-mid forecast period due to patent expiries for key products, which will lead to increased generic competition[1].

Price Projections

The prices of mirabegron are subject to various factors, including pharmacy location, insurance coverage, and the availability of generic versions.

• Current Pricing:
  • Mirabegron 25 mg oral tablet, extended release: around $432 for a supply of 30 tablets[2].
  • Myrbetriq 25 mg oral tablet, extended release: around $494 for a supply of 30 tablets[5].
• Generic Versions: The availability of generic versions of mirabegron is expected to reduce costs and increase market accessibility. For example, a generic version of mirabegron can cost as low as $432.05 for 30 tablets[2][5].

Market Opportunities

There are several opportunities that could further boost the market for mirabegron:

• Development of Generic Alternatives: As patents expire, the development of generic alternatives will capture cost-conscious consumers and expand market reach[4].
• Leveraging Artificial Intelligence: Using AI to predict patient response and personalize doses could enhance the efficacy and appeal of mirabegron[4].
• Educational Outreach Programs: Targeted educational programs for urologists can increase prescription rates and improve market penetration[4].

Competitive Landscape

The competitive landscape for mirabegron is characterized by:

• Dominant Market Share: Mirabegron, particularly under the brand name Myrbetriq, holds a significant market share. In 2021, Myrbetriq accounted for a market share of 52.6% in the OAB drug market[1].
• Strategic Partnerships and R&D: Companies are investing in research and development to explore new therapeutic applications for mirabegron and to navigate regulatory challenges effectively[4].

Regional Scope

The market for mirabegron is global, with significant presence in:

• North America: A major market due to high healthcare spending and advanced diagnostic capabilities.
• Europe: Another key region with a large patient base and strong healthcare infrastructure.
• Asia Pacific: Growing rapidly due to increasing healthcare awareness and a large population base[3].

Porter’s Five Forces Analysis

To understand the competitive position of mirabegron in the market, a Porter’s Five Forces analysis is useful:

• Threat of New Entrants: High barriers to entry due to regulatory requirements and the need for significant R&D investments.
• Bargaining Power of Suppliers: Moderate, as the supply chain for pharmaceuticals is complex but generally stable.
• Bargaining Power of Buyers: Moderate to high, especially with the rise of generic alternatives and patient awareness.
• Threat of Substitute Products: Moderate, as alternative therapies exist but mirabegron’s unique mechanism of action provides a competitive edge.
• Competitive Rivalry Among Existing Competitors: High, due to the presence of other OAB treatments and the impending generic competition[4].

Key Takeaways

• The global OAB drug market, driven by mirabegron, is expected to grow steadily over the next decade.
• High drug costs and limited insurance coverage are significant restraints.
• Generic versions and educational outreach programs offer opportunities for market expansion.
• The competitive landscape is dominated by Myrbetriq, with strategic partnerships and R&D playing crucial roles.

FAQs

Q: What is mirabegron used for? A: Mirabegron is used primarily for the treatment of overactive bladder (OAB), helping to reduce urinary frequency and incontinence.

Q: How does mirabegron work? A: Mirabegron works by activating beta-3 adrenergic receptors in the bladder, allowing the bladder to relax and store more urine.

Q: What are the current prices for mirabegron? A: The cost for mirabegron 25 mg oral tablet, extended release, is around $432 to $494 for a supply of 30 tablets, depending on the pharmacy and whether it is the brand name or generic version.

Q: Are there generic versions of mirabegron available? A: Yes, generic versions of mirabegron are available, which can reduce costs and increase market accessibility.

Q: What are the main drivers of the mirabegron market? A: The main drivers include the increasing prevalence of OAB, growing geriatric populations, and heightened healthcare awareness.

Sources

1. ResearchAndMarkets.com: "Overactive Bladder - Global Drug Forecast and Market Analysis to 2030"[1].
2. Drugs.com: "Mirabegron Prices, Coupons, Copay Cards & Patient Assistance"[2].
3. Biospace: "Overactive Bladder Treatment Market (Pharmacotherapy, Disease Type) to Reach $5.33bn by 2028 at 3.1% CAGR with Mirabegron Segment Driving Growth During 2022-2028 - The Insight Partners"[3].
4. 360iResearch: "Mirabegron Drugs Market Size & Share 2025-2030"[4].
5. Drugs.com: "Myrbetriq Prices, Coupons, Copay Cards & Patient Assistance"[5].

Last updated: 2025-01-02